Based on the Cipla Limited stock forecast from 4 analysts, the average analyst target price for Cipla Limited is INR 1,667.25 over the next 12 months. Cipla Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cipla Limited is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Cipla Limited’s stock price was INR 1,486.50. Cipla Limited’s stock price has changed by -0.88% over the past week, -1.58% over the past month and +16.91% over the last year.
No recent analyst target price found for Cipla Limited
No recent average analyst rating found for Cipla Limited
Company Overview Cipla Limited
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Address: Cipla House, Mumbai, India, 400013 Read Less
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It off...Read More
Frequently Asked Questions About Cipla Limited (CIPLA:NSE) Stock
Based on ratings from 4 analysts Cipla Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 1 hold ratings.
CIPLA:NSE stock's dividend yield is 0.87%.
Our analysis grades CIPLA:NSE stock's dividend yield at D-. This means that CIPLA:NSE stock's dividend yield is above 60% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be a average dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for CIPLA:NSE is INR 1,667.25 over the next 12 months. The maximum analyst target price is INR 1776 while the minimum anlayst target price is INR 1560.
CIPLA:NSE stock's Price/Earning ratio is 26.81.
Our analysis grades CIPLA:NSE stock's Price / Earning ratio at B-. This means that CIPLA:NSE stock's Price/Earning ratio is above 20% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be undervalued for its sector.
The last closing price of CIPLA:NSE's stock was INR 1,486.50.
The most recent market capitalization for CIPLA:NSE is INR 1,200.52B.
Based on targets from 4 analysts, the average taret price for CIPLA:NSE is projected at INR 1,667.25 over the next 12 months.
This means that CIPLA:NSE's stock price may go up by +12.16% over the next 12 months.
We can't find any ETFs which contains Cipla Limited's stock.
As per our most recent records Cipla Limited has 27,764 Employees.
Cipla Limited's registered address is Cipla House, Mumbai, India, 400013.
You can get more information about it from Cipla Limited's website at https://www.cipla.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Frequently Asked Questions About Cipla Limited (CIPLA:NSE) Stock
Based on ratings from 4 analysts Cipla Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 1 hold ratings.
CIPLA:NSE stock's dividend yield is 0.87%.
Our analysis grades CIPLA:NSE stock's dividend yield at D-. This means that CIPLA:NSE stock's dividend yield is above 60% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be a average dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for CIPLA:NSE is INR 1,667.25 over the next 12 months. The maximum analyst target price is INR 1776 while the minimum anlayst target price is INR 1560.
CIPLA:NSE stock's Price/Earning ratio is 26.81.
Our analysis grades CIPLA:NSE stock's Price / Earning ratio at B-. This means that CIPLA:NSE stock's Price/Earning ratio is above 20% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be undervalued for its sector.
The last closing price of CIPLA:NSE's stock was INR 1,486.50.
The most recent market capitalization for CIPLA:NSE is INR 1,200.52B.
Based on targets from 4 analysts, the average taret price for CIPLA:NSE is projected at INR 1,667.25 over the next 12 months.
This means that CIPLA:NSE's stock price may go up by +12.16% over the next 12 months.
We can't find any ETFs which contains Cipla Limited's stock.
As per our most recent records Cipla Limited has 27,764 Employees.
Cipla Limited's registered address is Cipla House, Mumbai, India, 400013.
You can get more information about it from Cipla Limited's website at https://www.cipla.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CIPLA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
